经支气管冷冻活检在纤维化间质性肺病中的操作改良降低风险
这项前瞻性研究纳入61例纤维化间质性肺病患者,评估经支气管冷冻活检(CryoTBB)的效能及操作改良的效果。对前19例中期分析后引入的操作改良使并发症率从84%显著降至14%(p<0.001),30天死亡率为2%,CryoTBB在46/61例(75%)中获确切诊断,仅21%患者转行外科肺活检。
要点
- 操作改良使CryoTBB并发症率从84%降至14%(p<0.001)。
- CryoTBB在75%(46/61)纤维化间质性肺病患者中获确切诊断。
- 仅21%患者需转行外科肺活检,30天死亡率为2%。
核心结论
- 操作改良显著降低经支气管冷冻活检的并发症率,但未消除严重并发症风险。
- 以CryoTBB起始、外科肺活检作为可选升级步骤的算法可行,且多数患者获确切诊断。
研究设计与样本
- 前瞻性分析61例纤维化间质性肺病患者,评估CryoTBB效能及操作改良效果。
- 操作改良在前19例中期分析后引入。
主要发现
- 操作改良使并发症率从84%降至14%(p<0.001)。
- 30天死亡率为2%。
- CryoTBB在46/61例(75%)中获确切诊断。
- 仅21%患者转行外科肺活检。
关键数值与推荐
- CryoTBB起始、外科肺活检作为可选升级步骤的算法可行。
- 因改良后仍存在严重并发症风险,组织取样应限于确切诊断可指导延长生存治疗的患者。
临床怎么用
- 对纤维化间质性肺病患者可行CryoTBB起始诊断,必要时升级至外科肺活检。
- 采用改良操作流程以降低并发症风险。
- 组织取样前评估患者是否具备通过确切诊断获得延长生存治疗的条件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sixty-one subjects with fibrosing interstitial lung disease were prospectively analysed to determine the efficacy of transbronchial cryobiopsy (CryoTBB) and the effect of procedural modifications which were introduced after an interim analysis of the first 19 subjects. The modifications significantly reduced complication rates from 84% to 14% (p<0.001). 30-day-mortality was 2%. The algorithm with initial CryoTBB and surgical lung biopsy (SLB) as optional step-up procedure was feasible. CryoTBB led to a confident diagnosis in 46/61 subjects (75%). Only 21% out of all subjects were forwarded for SLB. As the modified CryoTBB reduced but not eliminated the risk of severe complications, tissue sampling should be limited to patients where confident diagnosis enables life prolonging therapy. Trial registration number: NCT01714518.
引用
- Hagmeyer L, Theegarten D, Wohlschläger J, et al. Transbronchial cryobiopsy in fibrosing interstitial lung disease: modifications of the procedure lead to risk reduction. Thorax. 2019. PMID: 30852561. doi:10.1136/thoraxjnl-2018-212095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。